Nektar Therapeutics (NKTR) Cash & Current Investments (2016 - 2025)
Historic Cash & Current Investments for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to $270.2 million.
- Nektar Therapeutics' Cash & Current Investments rose 1051.68% to $270.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $270.2 million, marking a year-over-year increase of 1051.68%. This contributed to the annual value of $255.2 million for FY2024, which is 1593.79% down from last year.
- As of Q3 2025, Nektar Therapeutics' Cash & Current Investments stood at $270.2 million, which was up 1051.68% from $175.9 million recorded in Q2 2025.
- In the past 5 years, Nektar Therapeutics' Cash & Current Investments registered a high of $1.0 billion during Q1 2021, and its lowest value of $175.9 million during Q2 2025.
- In the last 5 years, Nektar Therapeutics' Cash & Current Investments had a median value of $409.4 million in 2023 and averaged $489.3 million.
- Per our database at Business Quant, Nektar Therapeutics' Cash & Current Investments plummeted by 4067.97% in 2022 and then soared by 1051.68% in 2025.
- Quarter analysis of 5 years shows Nektar Therapeutics' Cash & Current Investments stood at $734.0 million in 2021, then crashed by 31.2% to $505.0 million in 2022, then plummeted by 39.88% to $303.6 million in 2023, then fell by 15.94% to $255.2 million in 2024, then rose by 5.87% to $270.2 million in 2025.
- Its Cash & Current Investments was $270.2 million in Q3 2025, compared to $175.9 million in Q2 2025 and $218.6 million in Q1 2025.